Cent Eur J Public Health 2020, 28(1):53-58 | DOI: 10.21101/cejph.a5620

Impact of smoking on metabolic changes and effectiveness of drugs used for lung cancer

František Perlík1,2
1 Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
2 Institute for Postgraduate Medical Education, Prague, Czech Republic

Objective: This article reviews the published studies dealing with the influence of cigarette smoking on metabolic changes and effectiveness of drugs used in the systemic chemotherapy of the lung cancer.

Methods: The literature search of interactions between cigarette smoking and drugs used for lung cancer was carried out. The abstracted data mostly involved some induction of key drug-metabolizing enzymes of cytochrome CYP1A1/2, CYP2D6, CYP3A4 and isoforms of UDP-glucuronosyltransferase.

Results: Metabolic changes are important both in the non-chemotherapy and for the drugs used in the chemotherapy. They can change pharmacokinetic and pharmacodynamic effects of drugs. Primarily, we addressed potential differences in drug effects on smokers and non-smokers. The increased clearance of erlotinib and irinotecan may have impact on effectiveness of the lung cancer therapy. The effects of taxanes and gemcitabine are more complex.

Conclusion: The evaluated studies show that continued smoking after lung cancer diagnosis is related to poor prognosis, reduced survival, risk of second primary malignancies, and increased cancer recurrence. Of particular importance is the deterioration in the quality of life and an increased incidence of the adverse drug reactions in smokers. The patient's cigarette smoking history should be considered carefully and smoking cessation must be taken into account.

Keywords: cigarette smoking, lung cancer, chemotherapy, cytochrome P450

Received: November 26, 2018; Revised: November 17, 2019; Accepted: November 17, 2019; Published: March 30, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Perlík F. Impact of smoking on metabolic changes and effectiveness of drugs used for lung cancer. Cent Eur J Public Health. 2020;28(1):53-58. doi: 10.21101/cejph.a5620. PubMed PMID: 32228818.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Csémy L FA, Kodl M, Skývová M. Tobacco and alcohol use in the Czech Republic 2018. Praha: Státní zdravotní ústav; 2019. (In Czech.)
    2. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007;64(18):1917-21. Go to original source... Go to PubMed...
    3. Hukkanen J. Induction of cytochrome P450 enzymes: a view on human in vivo findings. Expert Rev Clin Pharmacol. 2012;5(5):569-85. Go to original source... Go to PubMed...
    4. O'Malley M, King AN, Conte M, Ellingrod VL, Ramnath N. Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. J Thorac Oncol. 2014;9(7):917-26. Go to original source... Go to PubMed...
    5. Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm. 1996;24(5):461-73. Go to original source... Go to PubMed...
    6. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC, et al. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst. 1990;82(16):1333-9. Go to original source... Go to PubMed...
    7. Palma BB, Silva ESM, Vosmeer CR, Lastdrager J, Rueff J, Vermeulen NP, et al. Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression. Pharmacogenomics J. 2010;10(6):478-88. Go to original source... Go to PubMed...
    8. Zhou SF, Wang B, Yang LP, Liu JP. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev. 2010;42(2):268-354. Go to original source... Go to PubMed...
    9. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet. 1999;36(6):425-38. Go to original source... Go to PubMed...
    10. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci. 2001;58(5-6):737-47. Go to original source... Go to PubMed...
    11. Buzkova H, Pechandova K, Slanar O, Perlik F. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population. Cell Biochem Funct. 2008;26(1):76-81. Go to original source... Go to PubMed...
    12. Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol. 1997;43:7-35. Go to original source... Go to PubMed...
    13. Li J, Bluth MH. Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. Pharmgenomics Pers Med. 2011;4:11-33. Go to original source...
    14. Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71. Go to original source... Go to PubMed...
    15. Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project - part 2). J Thorac Oncol. 2012;7(10):1490-502. Go to original source... Go to PubMed...
    16. Polychronidou G, Papakotoulas P. Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report. Case Rep Oncol. 2013;6(1):189-96. Go to original source... Go to PubMed...
    17. Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, et al.; Okayama Lung Cancer Study Group. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J Thorac Oncol. 2010 Jan;5(1):99-104. Go to original source... Go to PubMed...
    18. de Graan AJ, Loos WJ, Friberg LE, Baker SD, van der Bol JM, van Doorn L, et al. Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Clin Cancer Res. 2012 Aug 15;18(16):4425-32. Go to original source... Go to PubMed...
    19. van der Bol JM, Mathijssen RH, Loos WJ, Friberg LE, van Schaik RH, de Jonge MJ, et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol. 2007;25(19):2719-26. Go to original source... Go to PubMed...
    20. Kanai M, Morita S, Matsumoto S, Nishimura T, Hatano E, Yazumi S, et al. A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. Ann Oncol. 2009;20(8):1397-401. Go to original source... Go to PubMed...
    21. Hukkanen J, Jacob P, 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57(1):79-115. Go to original source... Go to PubMed...
    22. Schuz J, Espina C, Villain P, Herrero R, Leon ME, Minozzi S, et al. European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer Epidemiol. 2015;39 Suppl 1:S1-10. Go to original source... Go to PubMed...
    23. Chen J, Jiang R, Garces YI, Jatoi A, Stoddard SM, Sun Z, et al. Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer. 2010;67(2):221-6. Go to original source... Go to PubMed...
    24. Zhou W, Heist RS, Liu G, Park S, Neuberg DS, Asomaning K, et al. Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. Lung Cancer. 2006;53(3):375-80. Go to original source... Go to PubMed...
    25. Florou AN, Gkiozos IC, Tsagouli SK, Souliotis KN, Syrigos KN. Clinical significance of smoking cessation in subjects with cancer: a 30-year review. Respir Care. 2014;59(12):1924-36. Go to original source... Go to PubMed...
    26. Condoluci A, Mazzara C, Zoccoli A, Pezzuto A, Tonini G. Impact of smoking on lung cancer treatment effectiveness: a review. Future Oncol. 2016;12(18):2149-61. Go to original source... Go to PubMed...
    27. Nayan S, Gupta MK, Sommer DD. Evaluating smoking cessation interventions and cessation rates in cancer patients: a systematic review and meta-analysis. ISRN Oncol. 2011;2011:849023. Go to original source... Go to PubMed...
    28. Zvolská K, Fraser K, Zvolský M, Králíková E. Treatment of tobacco Dependence, a Critical Gap in Czech Clinical Practice Guidelines. Cent Eur J Public Health. 2017;25(2):141-4. Go to original source... Go to PubMed...
    29. Warren GW, Alberg AJ, Kraft AS, Cummings KM. The 2014 Surgeon General's report: "The health consequences of smoking - 50 years of progress": a paradigm shift in cancer care. Cancer. 2014;120(13):1914-6. Go to original source... Go to PubMed...
    30. Johnston-Early A, Cohen MH, Minna JD, Paxton LM, Fossieck BE, Jr., Ihde DC, et al. Smoking abstinence and small cell lung cancer survival. An association. JAMA. 1980;244(19):2175-9. Go to original source... Go to PubMed...
    31. Tucker MA, Murray N, Shaw EG, Ettinger DS, Mabry M, Huber MH, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst. 1997;89(23):1782-8. Go to original source... Go to PubMed...
    32. Videtic GM, Stitt LW, Dar AR, Kocha WI, Tomiak AT, Truong PT, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol. 2003;21(8):1544-9. Go to original source... Go to PubMed...
    33. Garces YI, Yang P, Parkinson J, Zhao X, Wampfler JA, Ebbert JO, et al. The relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest. 2004;126(6):1733-41. Go to original source... Go to PubMed...
    34. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005 Sep 15;11(18):6414-21. Go to original source... Go to PubMed...
    35. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-32. Go to original source... Go to PubMed...
    36. Baser S, Shannon VR, Eapen GA, Jimenez CA, Onn A, Lin E, et al. Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest. 2006;130(6):1784-90. Go to original source... Go to PubMed...
    37. Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, Seymour L, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer. 2006;7(6):389-94. Go to original source... Go to PubMed...
    38. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer. 2006;106(11):2428-36. Go to original source... Go to PubMed...
    39. Balduyck B, Sardari Nia P, Cogen A, Dockx Y, Lauwers P, Hendriks J, et al. The effect of smoking cessation on quality of life after lung cancer surgery. Eur J Cardiothorac Surg. 2011;40(6):1432-7; discussion 7-8. Go to original source... Go to PubMed...
    40. Weiss JM, Villaruz LC, O'Brien J, Ivanova A, Lee C, Olson JG, et al. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer. Clin Lung Cancer. 2016;17(2):128-32. Go to original source... Go to PubMed...

    Return to the content